Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells.

König A, Yang J, Jo E, Park KHP, Kim H, Than TT, Song X, Qi X, Dai X, Park S, Shum D, Ryu WS, Kim JH, Yoon SK, Park JY, Ahn SH, Han KH, Gerlich WH, Windisch MP.

J Hepatol. 2019 Aug;71(2):289-300. doi: 10.1016/j.jhep.2019.04.010. Epub 2019 May 8.

2.

High Environmental Stability of Hepatitis B Virus and Inactivation Requirements for Chemical Biocides.

Than TT, Jo E, Todt D, Nguyen PH, Steinmann J, Steinmann E, Windisch MP.

J Infect Dis. 2019 Mar 15;219(7):1044-1048. doi: 10.1093/infdis/jiy620.

3.

High-throughput drug screening using the Ebola virus transcription- and replication-competent virus-like particle system.

Lee N, Shum D, König A, Kim H, Heo J, Min S, Lee J, Ko Y, Choi I, Lee H, Radu C, Hoenen T, Min JY, Windisch MP.

Antiviral Res. 2018 Oct;158:226-237. doi: 10.1016/j.antiviral.2018.08.013. Epub 2018 Aug 24.

4.

Suppression of Hepatitis C Virus Genome Replication and Particle Production by a Novel Diacylglycerol Acyltransferases Inhibitor.

Kim D, Goo JI, Kim MI, Lee SJ, Choi M, Than TT, Nguyen PH, Windisch MP, Lee K, Choi Y, Lee C.

Molecules. 2018 Aug 20;23(8). pii: E2083. doi: 10.3390/molecules23082083.

5.

Virtual Screening in Hepatitis B Virus Drug Discovery: Current Stateof- the-Art and Future Perspectives.

Elmessaoudi-Idrissi M, Blondel A, Kettani A, Windisch MP, Benjelloun S, Ezzikouri S.

Curr Med Chem. 2018;25(23):2709-2721. doi: 10.2174/0929867325666180221141451. Review.

PMID:
29473495
6.

Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins.

Bulanova D, Ianevski A, Bugai A, Akimov Y, Kuivanen S, Paavilainen H, Kakkola L, Nandania J, Turunen L, Ohman T, Ala-Hongisto H, Pesonen HM, Kuisma MS, Honkimaa A, Walton EL, Oksenych V, Lorey MB, Guschin D, Shim J, Kim J, Than TT, Chang SY, Hukkanen V, Kulesskiy E, Marjomaki VS, Julkunen I, Nyman TA, Matikainen S, Saarela JS, Sane F, Hober D, Gabriel G, De Brabander JK, Martikainen M, Windisch MP, Min JY, Bruzzone R, Aittokallio T, Vähä-Koskela M, Vapalahti O, Pulk A, Velagapudi V, Kainov DE.

Viruses. 2017 Sep 25;9(10). pii: E271. doi: 10.3390/v9100271.

7.

Characterization and structure-activity relationship study of iminodipyridinopyrimidines as novel hepatitis C virus inhibitor.

Park DS, Jo E, Choi J, Lee M, Kim S, Kim HY, Nam J, Ahn S, Hwang JY, Windisch MP.

Eur J Med Chem. 2017 Nov 10;140:65-73. doi: 10.1016/j.ejmech.2017.09.010. Epub 2017 Sep 6.

PMID:
28923387
8.

Abl Tyrosine Kinase Regulates Hepatitis C Virus Entry.

Min S, Lim YS, Shin D, Park C, Park JB, Kim S, Windisch MP, Hwang SB.

Front Microbiol. 2017 Jun 19;8:1129. doi: 10.3389/fmicb.2017.01129. eCollection 2017.

9.

Virucidal Activity of World Health Organization-Recommended Formulations Against Enveloped Viruses, Including Zika, Ebola, and Emerging Coronaviruses.

Siddharta A, Pfaender S, Vielle NJ, Dijkman R, Friesland M, Becker B, Yang J, Engelmann M, Todt D, Windisch MP, Brill FH, Steinmann J, Steinmann J, Becker S, Alves MP, Pietschmann T, Eickmann M, Thiel V, Steinmann E.

J Infect Dis. 2017 Mar 15;215(6):902-906. doi: 10.1093/infdis/jix046.

10.

GRIM-19 Restricts HCV Replication by Attenuating Intracellular Lipid Accumulation.

Kim JH, Sung PS, Lee EB, Hur W, Park DJ, Shin EC, Windisch MP, Yoon SK.

Front Microbiol. 2017 Apr 11;8:576. doi: 10.3389/fmicb.2017.00576. eCollection 2017.

11.

A Novel Inhibitor IDPP Interferes with Entry and Egress of HCV by Targeting Glycoprotein E1 in a Genotype-Specific Manner.

Lee M, Yang J, Jo E, Lee JY, Kim HY, Bartenschlager R, Shin EC, Bae YS, Windisch MP.

Sci Rep. 2017 Mar 23;7:44676. doi: 10.1038/srep44676.

12.

TALEN/CRISPR-mediated engineering of a promoterless anti-viral RNAi hairpin into an endogenous miRNA locus.

Senís E, Mockenhaupt S, Rupp D, Bauer T, Paramasivam N, Knapp B, Gronych J, Grosse S, Windisch MP, Schmidt F, Theis FJ, Eils R, Lichter P, Schlesner M, Bartenschlager R, Grimm D.

Nucleic Acids Res. 2017 Jan 9;45(1):e3. doi: 10.1093/nar/gkw805. Epub 2016 Sep 9.

13.

In Silico Design and Experimental Validation of siRNAs Targeting Conserved Regions of Multiple Hepatitis C Virus Genotypes.

ElHefnawi M, Kim T, Kamar MA, Min S, Hassan NM, El-Ahwany E, Kim H, Zada S, Amer M, Windisch MP.

PLoS One. 2016 Jul 21;11(7):e0159211. doi: 10.1371/journal.pone.0159211. eCollection 2016.

14.

Micrococcin P1, a naturally occurring macrocyclic peptide inhibiting hepatitis C virus entry in a pan-genotypic manner.

Lee M, Yang J, Park S, Jo E, Kim HY, Bae YS, Windisch MP.

Antiviral Res. 2016 Aug;132:287-95. doi: 10.1016/j.antiviral.2016.07.002. Epub 2016 Jul 4.

PMID:
27387825
15.

Type I and type II interferon responses in two human liver cell lines (Huh-7 and HuH6).

Grünvogel O, Esser-Nobis K, Windisch MP, Frese M, Trippler M, Bartenschlager R, Lohmann V, Binder M.

Genom Data. 2015 Dec 28;7:166-70. doi: 10.1016/j.gdata.2015.12.017. eCollection 2016 Mar.

16.

Benzothiazepinecarboxamides: Novel hepatitis C virus inhibitors that interfere with viral entry and the generation of infectious virions.

Kim HY, Kong S, Oh S, Yang J, Jo E, Ko Y, Kim SH, Hwang JY, Song R, Windisch MP.

Antiviral Res. 2016 May;129:39-46. doi: 10.1016/j.antiviral.2016.01.010. Epub 2016 Feb 2.

PMID:
26850830
17.

Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections.

Yang S, K R J, Lim S, Choi TG, Kim JH, Akter S, Jang M, Ahn HJ, Kim HY, Windisch MP, Khadka DB, Zhao C, Jin Y, Kang I, Ha J, Oh BC, Kim M, Kim SS, Cho WJ.

J Med Chem. 2015 Dec 24;58(24):9546-61. doi: 10.1021/acs.jmedchem.5b01064. Epub 2015 Dec 8.

PMID:
26613291
18.

Development of a novel hepatitis B virus encapsidation detection assay by viral nucleocapsid-captured quantitative RT-PCR.

Ryu DK, Ahn Y, Ryu WS, Windisch MP.

Biotechniques. 2015 Nov 1;59(5):287-93. doi: 10.2144/000114354. eCollection 2015 Nov.

19.

Identification of a resveratrol tetramer as a potent inhibitor of hepatitis C virus helicase.

Lee S, Yoon KD, Lee M, Cho Y, Choi G, Jang H, Kim B, Jung DH, Oh JG, Kim GW, Oh JW, Jeong YJ, Kwon HJ, Bae SK, Min DH, Windisch MP, Heo TH, Lee C.

Br J Pharmacol. 2016 Jan;173(1):191-211. doi: 10.1111/bph.13358. Epub 2015 Nov 25.

20.

DDX60L Is an Interferon-Stimulated Gene Product Restricting Hepatitis C Virus Replication in Cell Culture.

Grünvogel O, Esser-Nobis K, Reustle A, Schult P, Müller B, Metz P, Trippler M, Windisch MP, Frese M, Binder M, Fackler O, Bartenschlager R, Ruggieri A, Lohmann V.

J Virol. 2015 Oct;89(20):10548-68. doi: 10.1128/JVI.01297-15. Epub 2015 Aug 12.

21.

The FDA-approved drug irbesartan inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate co-transporting polypeptide.

Ko C, Park WJ, Park S, Kim S, Windisch MP, Ryu WS.

Antivir Ther. 2015;20(8):835-42. doi: 10.3851/IMP2965. Epub 2015 May 1.

PMID:
25929767
22.

DDX3 DEAD-box RNA helicase is a host factor that restricts hepatitis B virus replication at the transcriptional level.

Ko C, Lee S, Windisch MP, Ryu WS.

J Virol. 2014 Dec;88(23):13689-98. doi: 10.1128/JVI.02035-14. Epub 2014 Sep 17.

23.

Discovery of 2-iminobenzimidazoles as potent hepatitis C virus inhibitors with a novel mechanism of action.

Windisch MP, Jo S, Kim HY, Kim SH, Kim K, Kong S, Jeong H, Ahn S, No Z, Hwang JY.

Eur J Med Chem. 2014 May 6;78:35-42. doi: 10.1016/j.ejmech.2014.03.030. Epub 2014 Mar 13.

PMID:
24675178
24.

Synthesis and evaluation of hexahydropyrimidines and diamines as novel hepatitis C virus inhibitors.

Hwang JY, Kim HY, Jo S, Park E, Choi J, Kong S, Park DS, Heo JM, Lee JS, Ko Y, Choi I, Cechetto J, Kim J, Lee J, No Z, Windisch MP.

Eur J Med Chem. 2013;70:315-25. doi: 10.1016/j.ejmech.2013.09.055. Epub 2013 Oct 6.

PMID:
24177358
25.

Identification of a series of 1,3,4-trisubstituted pyrazoles as novel hepatitis C virus entry inhibitors.

Hwang JY, Kim HY, Park DS, Choi J, Baek SM, Kim K, Kim S, Seong S, Choi I, Lee HG, Windisch MP, Lee J.

Bioorg Med Chem Lett. 2013 Dec 1;23(23):6467-73. doi: 10.1016/j.bmcl.2013.09.039. Epub 2013 Sep 21.

PMID:
24125883
26.

Development of a multiplex phenotypic cell-based high throughput screening assay to identify novel hepatitis C virus antivirals.

Kim HY, Li X, Jones CT, Rice CM, Garcia JM, Genovesio A, Hansen MA, Windisch MP.

Antiviral Res. 2013 Jul;99(1):6-11. doi: 10.1016/j.antiviral.2013.04.020. Epub 2013 May 6.

27.

High content screening of a kinase-focused library reveals compounds broadly-active against dengue viruses.

Cruz DJ, Koishi AC, Taniguchi JB, Li X, Milan Bonotto R, No JH, Kim KH, Baek S, Kim HY, Windisch MP, Pamplona Mosimann AL, de Borba L, Liuzzi M, Hansen MA, Duarte dos Santos CN, Freitas-Junior LH.

PLoS Negl Trop Dis. 2013;7(2):e2073. doi: 10.1371/journal.pntd.0002073. Epub 2013 Feb 21.

28.

Low oxygen tension enhances hepatitis C virus replication.

Vassilaki N, Kalliampakou KI, Kotta-Loizou I, Befani C, Liakos P, Simos G, Mentis AF, Kalliaropoulos A, Doumba PP, Smirlis D, Foka P, Bauhofer O, Poenisch M, Windisch MP, Lee ME, Koskinas J, Bartenschlager R, Mavromara P.

J Virol. 2013 Mar;87(5):2935-48. doi: 10.1128/JVI.02534-12. Epub 2012 Dec 26.

29.

Discovery and characterization of a novel 7-aminopyrazolo[1,5-a]pyrimidine analog as a potent hepatitis C virus inhibitor.

Hwang JY, Windisch MP, Jo S, Kim K, Kong S, Kim HC, Kim S, Kim H, Lee ME, Kim Y, Choi J, Park DS, Park E, Kwon J, Nam J, Ahn S, Cechetto J, Kim J, Liuzzi M, No Z, Lee J.

Bioorg Med Chem Lett. 2012 Dec 15;22(24):7297-301. doi: 10.1016/j.bmcl.2012.10.123. Epub 2012 Nov 5.

PMID:
23159569
30.

Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication.

Metz P, Dazert E, Ruggieri A, Mazur J, Kaderali L, Kaul A, Zeuge U, Windisch MP, Trippler M, Lohmann V, Binder M, Frese M, Bartenschlager R.

Hepatology. 2012 Dec;56(6):2082-93. doi: 10.1002/hep.25908. Epub 2012 Oct 14.

PMID:
22711689
31.

Automated genome-wide visual profiling of cellular proteins involved in HIV infection.

Genovesio A, Kwon YJ, Windisch MP, Kim NY, Choi SY, Kim HC, Jung S, Mammano F, Perrin V, Boese AS, Casartelli N, Schwartz O, Nehrbass U, Emans N.

J Biomol Screen. 2011 Oct;16(9):945-58. doi: 10.1177/1087057111415521. Epub 2011 Aug 12.

PMID:
21841144
32.

Mouse hepatic cells support assembly of infectious hepatitis C virus particles.

Long G, Hiet MS, Windisch MP, Lee JY, Lohmann V, Bartenschlager R.

Gastroenterology. 2011 Sep;141(3):1057-66. doi: 10.1053/j.gastro.2011.06.010. Epub 2011 Jun 13.

PMID:
21699799
33.

Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line.

Haid S, Windisch MP, Bartenschlager R, Pietschmann T.

J Virol. 2010 Jan;84(2):964-75. doi: 10.1128/JVI.01504-09. Epub 2009 Nov 4.

34.

Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methylcytidine, the active component of valopicitabine.

Coelmont L, Paeshuyse J, Windisch MP, De Clercq E, Bartenschlager R, Neyts J.

Antimicrob Agents Chemother. 2006 Oct;50(10):3444-6.

35.

Dissecting the interferon-induced inhibition of hepatitis C virus replication by using a novel host cell line.

Windisch MP, Frese M, Kaul A, Trippler M, Lohmann V, Bartenschlager R.

J Virol. 2005 Nov;79(21):13778-93.

36.

Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs.

Krönke J, Kittler R, Buchholz F, Windisch MP, Pietschmann T, Bartenschlager R, Frese M.

J Virol. 2004 Apr;78(7):3436-46.

Supplemental Content

Loading ...
Support Center